2025 |
||
| 28 February | CN 04-2025 | 4.2: Staffing and training principles for donation sessions 4.3: Clinical leadership at donor sessions 4.7: Equipment and consumables 4.9: References |
| 24 January | CN 02-2025 | 7.5.7: Human Plasma for Fractionation, Cryoprecipitate Depleted, Leucocyte Depleted |
2024 |
||
| 07 October | CN 28-2024 | 5.10: Staffing and training principles for donation sessions 5.13: Clinical leadership at donor sessions Chapter 5, Appendix I - Serious Adverse Events of Donation (removed) |
| 17 May | CN 29-2024 | 7.5.6: Human Plasma for Fractionation, Leucocyte Depleted |
| 18 April | CN 05-2024 | Chapter 7: Requirements for the timing of testing for Hematopoietic Progenitor Cells (HPCs) Chapter 21: Tissue banking: tissue retrieval and processing |
| 13 March | CN 03-2024 | Chapter 2: Quality in blood and tissue establishments and hospital blood banks Chapter 6: Evaluation and manufacture of blood components Chapter 7: Specifications for blood components Annexe 3: Provisional Components Annexe 4: Redundant Components Annexe 5: Blood Components for Contingency Use |
2023 |
||
| 11 December | CN 40-2023 | 7.31: Irradiated components 9.2: Microbiology screening 9.3: Specific screening targets 9.4: Reinstatement of blood donors 9.7: Recommended standards for environmental monitoring (EM) of processing facilities |
| 02 November | CN 39-2023 | Annexe 7: Requirements for the timing of testing for HPCs |
| 04 September | CN 16-2023 | Chapter 4: Premises and quality assurance at blood donor sessions Chapter 5: Collection of a blood or component donation Chapter 11: Reagent manufacture Chapter 12: Donation testing (red cell immunohaematology) Chapter 13: Patient testing (red cell immunohaematology) Chapter 14: Guidelines for the use of DNA/PCR techniques in Blood Establishments Chapter 15: Molecular typing for red cell antigens Chapter 16: HLA typing and HLA serology Chapter 17: Granulocyte immunology Chapter 18: Platelet immunology Chapter 22: Haemopoietic progenitor cells Annexe 7: Requirements for the timing of testing for HPCs |
| 12 April | CN 22-2023 | Annexe 3.5: Red Cells and Plasma, Leucocyte Depleted |
| 13 February | CN 06-2023 | Chapter 9: Microbiology tests for donors and donations: general specifications for laboratory test procedures Chapter 10: Investigation of suspected transfusion-transmitted infection Chapter 19: Tissue Banking: general principles Chapter 20: Tissue Banking: selection of donors Chapter 21: Tissue Banking: tissue retrieval and processing Annexe 6: Advanced Therapy Medicinal Products (ATMPs) |
2022 |
||
| 22 June | CN 33-2022 | Chapter 8: Evaluation of novel blood components, production processes and blood packs: generic protocols |
| 22 March | CN 09-2022 | 7.5.6: Human Plasma for Fractionation, Leucocyte Depleted |
| 02 March | CN 10-2022 | Annexe 4: Redundant Components - Convalescent Plasma |
| 02 March | CN 11-2022 | Annexe 3: Provisional Components - Whole blood, leucocyte depleted, for clinical studies |
| 02 March | CN 12-2022 | Annexe 3: Provisional Components - Cryoprecipitate pooled, leucocyte depleted, extended shelf life post-thaw |
| 11 January | CN 44-2021 | Annexe 5: Blood Components for Contingency Use |
2021 |
||
| 22 June | CN 18-2021 | Chapter 3: - Care and selection of whole blood and component donors (including donors of pre-deposit autologous blood) |
| 12 January | CN 03-2021 | Chapter 21: Tissue banking: tissue retrieval and processing |
2020 |
||
| 17 November | CN 66-2020 | Annexe 3: Provisional Component - Convalescent Plasma (COVID-19), FFP, Leucocyte Depleted |
| 17 November | CN 67-2020 | Annexe 3: Provisional Component - Convalescent Plasma (COVID-19), FFP, for Neonates and Infants, Leucocyte Depleted |
| 26 October | CN 35-2020 | Annexe 3: Provisional Component - Whole Blood, Leucocyte Depleted for Clinical Studies |
| 16 September | CN 47-2020 | Annexe 5: Platelets, Apheresis, Leucocyte Depleted, at Reduced Dose as a Contingency |
| 08 June | CN 32-2020 | Annexe 3: Provisional Component - Red Cells and Plasma, Leucocyte Depleted |
| 06 May | CN 23-2020 | Chapter 7: Fresh Frozen Plasma for Neonates and Infants, Leucocyte Depleted |
| 06 May | CN 24-2020 | Chapter 7: Cryoprecipitate for Neonates and Infants, Leucocyte Depleted |
| 06 May | CN 25-2020 | Chapter 7: Fresh Frozen Plasma, Leucocyte Depleted |
| 07 May | CN 27-2020 | 3.15: Blood Tests |
| 21 April | CN 19-2020 | Annexe 4: Redundant Components |
| 21 April | CN 20-2020 | Annexe 4: Redundant Components - Granulocytes, Apheresis |
| 21 April | CN 21-2020 | Annexe 5: Blood Components for Contingency Use |
| 21 April | CN 22-2020 | Annexe 5.1: Red Cells in Additive Solution, Leucocyte Depleted, Extended Shelf Life |
2019 |
||
| 26 November | CN 34-2020 | Chapter 7: Platelets in Plasma and Additive Solution for Neonatal Use, Leucocyte Depleted |
2017 |
||
| 06 April | CN 10-2017 | Chapter 7: Use of plasma from first time donors |
| 27 January | CN 01-2017 | Chapter 11: General guidelines for reagent red cell manufacture |
| 27 January | CN 02-2017 | Chapter 17 and 18 - Additional guidance re HNA and HPA antibody detection methods |
2016 |
||
| 15 August | CN 32-2016 | Chapter 7: Red Cells, Thawed and Washed, Leucocyte Depleted |
| 15 August | CN 33-2016 | Chapter 7: Removal of red cells from a controlled temperature environment |
| 15 August | CN 34-2016 | Chapter 7: Removal of upper limit of pH from Platelet Components |
| 21 June | CN 31-2016 | Annexe 3: Trial Components |
| 11 May | CN 23-2016 | Chapter 21: Tissue banking: Tissue retrieval and processing |
| 01 April | CN 16-2016 | Chapter 7: Fresh Frozen Plasma, Leucocyte Depleted |
| 17 March | CN 12-2016 | Chapter 9: Microbiology tests for donors and donations: general specifications for laboratory test procedures |
2015 |
||
| 14 December | CN 30-2015 | Chapter 7: Red Cells, Washed, Leucocyte Depleted |
| 07 December | CN 18-2015 | Chapter 7: Interruptions to agitation and testing of Platelets, Pooled, Buffy Coat Derived, Leucocyte Depleted and Platelets, Apheresis, Leucocyte Depleted |
| 07 December | CN 19-2015 | Chapter 7: Platelets in Additive Solution and Plasma, Leucocyte Depleted |
| 07 December | CN 20-2015 | Chapter 6: Specific gravity of blood components |
| 07 December | CN 21-2015 | Chapter 7: Leucocyte depletion of blood components - Concessionary release |
| 07 December | CN 22-2015 | Chapter 7: Concessionary Release Limits for Selected Components |
| 07 December | CN 23-2015 | Chapter 9: Removal of Chapter 9.4.2. and Figure 9.6 |
| 07 December | CN 29-2015 | 25.6: Table 25.5: Protocol 000001 – blood component dispatch information |
| 21 January | CN 01-2015 | 25.6: Tables 25.4 and 25.5: Protocol 000001 – blood component dispatch information |
2014 |
||
| 09 May | CN 25-2014 | Chapter 5, Appendix I: Points of care |
2013 |
||
| 31 December | CN 15-2013 | Chapter 3, Appendix I: Extra-corporeal volume tables |
| 31 December | CN 16-2013 | 7.9.1: Platelets, Pooled, Buffy Coat Derived, Leucocyte Depleted 7.11.1: Platelets in Additive Solution and Plasma, Leucocyte Depleted 7.12.1: Platelets in Additive Solution, Leucocyte Depleted 9.5.3.1: Single-test system 12.11.2: Blood and blood components from group O donors with high titres of anti-A, anti-B and/or anti-A,B |
| 31 December | CN 17-2013 | 7.15: Fresh Frozen Plasma, Leucocyte Depleted 7.16: Fresh Frozen Plasma, Methylene Blue Treated and Removed, Leucocyte Depleted 7.17: Cryoprecipitate, Leucocyte Depleted 7.18: Cryoprecipitate Pooled, Leucocyte Depleted 7.20: Plasma, Cryoprecipitate Depleted, Leucocyte Depleted 7.27: Fresh Frozen Plasma, Neonatal Use, Methylene Blue Treated and Removed, Leucocyte Depleted 7.28: Cryoprecipitate, Methylene Blue Treated and Removed, Leucocyte Depleted 7.33: Cryoprecipitate, Pooled, Methylene Blue Treated and Removed, Leucocyte Depleted |
| 26 June | CN 11-2013 | 7.33: Cryoprecipitate, Pooled, Methylene Blue Treated and Removed, Leucocyte Depleted |
| 26 June | CN 12-2013 | Annexe 3: Platelets in Additive Solution and Plasma, Leucocyte Depleted, Pathogen-reduced |